Skip to main content

Table 1 Baseline characteristics

From: A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma

Characteristic Solid tumour N = 19 Haematological malignancy N = 28 Combined N = 47
Sex
 Male 9 18 27
 Female 10 10 20
Median age (range), years 59.2 (39.4–70.8) 49.0 (21.7–79.4) 53.1 (21.7–79.4)
Median no. of prior lines of systemic therapy (range) 2 (0–8) 4 (1–10) 3 (0–10)
ECOG performance status
 0 7 10 17
 1 12 18 30
Histology Colorectal 4 cHL 15  
Lung 4 DLBCL 3
Upper GI 3 AITL 4
Cervix 2 PTCLNOS 2
Endometrial 1 Indolent B-cell NHL 3
Breast 1 GZL 1
Peritoneal 1  
Neuroendocrine 1
Head and neck SCC 1
Meningioma 1
Stage
 III 0 4 N/A
 III or IIIS 2 6
 IV 17 18
Baseline HR23B status (IHC)
 Positive (6–7) 15 17 32
 Negative (0–5) 2 9 11
 Not available 2 2 4
  1. GI gastrointestinal, ECOG Eastern Cooperative Oncology Group, cHL classic Hodgkin lymphoma, AITL angio-immunoblastic T-cell lymphoma, DLBCL diffuse large B-cell lymphoma, GZL grey zone lymphoma, HR23B UV excision repair protein RAD23, IHC immunohistochemistry, NHL non-Hodgkin lymphoma, PTCLNOS Peripheral T-cell lymphoma not otherwise specified